Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Step N Grip, LLC, a company that sells rug accessories designed to keep rugs from curling at the corners, illegally invited its closest competitor to collude on prices. Under the FTC order, Step N Grip must stop communicating […]
Tag Archives: Bureau of Competition Competition
FTC Amicus Brief Urges Appeals Court to Reverse District Court Ruling that Incorrectly Insulates Pharmaceutical Manufacturers from Antitrust Scrutiny
The Federal Trade Commission filed an amicus brief in the U.S. Court of Appeals for the Third Circuit urging the court to reverse a district court ruling that an alleged reverse-payment settlement of patent litigation did not violate the antitrust laws, in part, because the FTC did not object to the proposed settlement when the […]
FTC Approves Final Order Requiring National Association of Animal Breeders to Eliminate Rules that Restrict Competition among Its Members
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the National Association of Animal Breeders restrained competition among its respective members through its code of ethics. Under the FTC order, the NAAB must stop imposing anticompetitive restrictions on its members’ advertising, and limiting their ability to […]
FTC Challenges Proposed Merger of Two West Virginia Hospitals
The Federal Trade Commission today authorized action to block Cabell Huntington Hospital’s proposed acquisition of St. Mary’s Medical Center – two hospitals located three miles apart in Huntington, West Virginia. The FTC issued an administrative complaint alleging that the combination would create a dominant firm with a near monopoly over general acute care inpatient hospital […]
FTC Amicus Brief Urges Appeals Court to Reverse Decision in Case of Alleged Discrimination in Package Sizes
The Federal Trade Commission filed an amicus brief in the U.S. Court of Appeals for the Seventh Circuit urging the court to reverse a district court decision finding that the mere sale of large-sized packages to one merchant but not another could violate Section 2(e) of the Robinson-Patman Act. The Act is a federal antitrust […]
FTC Requires Mylan to Sell Rights to Seven Generic Pharmaceuticals as a Condition of Acquiring Perrigo Company
Mylan N.V. has agreed to sell the rights and assets related to seven generic drugs in order to settle FTC charges that its proposed acquisition of Perrigo Company plc would be anticompetitive. Both companies market generic drugs globally, and according to the FTC complaint, as originally proposed, the acquisition would likely harm competition in U.S. […]
FTC Issues Final Orders Settling Charges of Illegal Agreement not to Compete
Following a public comment period, the Federal Trade Commission has approved final orders settling charges that pharmaceutical companies Concordia Pharmaceuticals Inc. and Par Pharmaceutical, Inc. entered into an unlawful agreement not to compete in the sale of generic versions of Kapvay, a prescription drug used to treat attention deficit hyperactivity disorder. Under the orders, first […]
Marketer of Rug Accessory Settles FTC Charges of Invitation to Collude with Competitor
A company that sells rug accessories designed to keep rugs from curling at the corners has agreed to settle Federal Trade Commission charges that it illegally invited its closest competitor to coordinate prices. The company, Step N Grip, LLC, sells NeverCurl, a product that can be attached to the corners of a rug so that […]
FTC Approves Final Order Preserving Competition in U.S. Markets for an Inhalation Solution and Three Injectable Products
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Pfizer Inc.’s $16 billion acquisition of Hospira, Inc. would likely be anticompetitive. Under the order, first announced in August 2015, the companies are required to divest Pfizer’s generic acetylcysteine inhalation solution, and Hospira’s clindamycin phosphate, voriconazole, and melphalan […]
Investor Len Blavatnik to Pay $656,000 to Settle FTC Charges That He Violated U.S. Premerger Notification Requirements
Investor Len Blavatnik has agreed to pay $656,000 in civil penalties to resolve Federal Trade Commission allegations that he violated federal premerger reporting laws by failing to report voting shares that he acquired in a California technology start up called TangoMe, in August 2014. TangoMe markets a cross-platform messaging application for smartphones that offers free […]